To compare the efficacy of topical levofloxacin and gatifloxacin at different durations in reducing conjunctival bacteria.
Methods:
In total, 285 patients (290 eyes) scheduled to undergo ophthalmic surgery were divided into 6 groups to receive either gatifloxacin or levofloxacin eye drops for 1 day (12 times/day), 2 days (6 times/day), or 3 days (4 times/day) before surgery. Conjunctival sac specimens were collected from all patients before treatment (T0) and after treatment (T1). All specimens were inoculated onto Columbia blood agar plates.
Results:
Before treatment, the culture positivity rate was 50.34% for 290 samples, and after treatment, the culture positivity rate was 11.72% (P < 0.05). Corynebacterium spp. and Staphylococcus spp. were the most predominantly detected microbial groups before and after treatment. The bacterial eradication rate was higher in the gatifloxacin group (87.01%) than in the levofloxacin group (81.15%). There was no difference in culture positivity between gatifloxacin 1-, 2-, and 3-day groups (P > 0.05). The culture positivity rate was significantly higher in the levofloxacin 1-day group than in the 2- and 3-day groups (P < 0.05). Both drugs were effective in removing gram-positive bacillus at different durations (P < 0.01), but only the levofloxacin treatment for 3 days significantly reduced the positive cultures of gram-positive cocci in the conjunctival sac (P < 0.05).
Conclusions:
Our study demonstrated that preoperative use of levofloxacin to prevent infection takes at least 2–3 days, and 1 day is a sufficient duration for topical gatifloxacin to significantly reduce conjunctival bacterial flora.
KeynanY, FinkelmanY, Lagacé-WiensP. The microbiology of endophthalmitis: Global trends and a local perspective. Eur J Clin Microbiol Infect Dis, 2012; 31(11):2879–2886.
2.
DurandML. Bacterial and fungal endophthalmitis. Clin Microbiol Rev, 2017; 30(3):597–613.
3.
SpeakerMG, MilchFA, ShahMK, et al.Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology, 1991; 98(5):639–649, 650.
LiB, MiñoDKH, HaritoglouC, et al.Comparison of 1-day versus 1-hour application of topical neomycin/polymyxin-B before cataract surgery. J Cataract Refract Surg, 2015; 41(4):724–731.
6.
MossJM, NguyenD, LiuYI, et al.Comparison of One-Day Versus One-Hour application of topical gatifloxacin in eliminating conjunctival bacterial flora. Ophthalmology, 2008; 115(11):2013–2016.
7.
Abdel-MeguidA, GabrAF, SaidMM, et al.Comparative study between topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a prophylactic measure before intraocular surgery. J Ocul Pharmacol Ther, 2019; 35(5):315–318.
8.
ChangDF, RheeDJ. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2021 ASCRS member survey. J Cataract Refract Surg, 2022; 48(1):3–7.
9.
GargP, KhorWB, RoyA, et al.A survey of Asian Eye Institutions on perioperative antibiotic prophylaxis in cataract surgery. Int Ophthalmol, 2023.
10.
GunaldaJ, WilliamsD, KoyfmanA, et al.High risk and low prevalence diseases: Endophthalmitis. Am J Emerg Med, 2023; 71:144–149.
11.
LiB, NentwichMM, HoffmannLE, et al.Comparison of the efficacy of povidone-iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery. J Cataract Refract Surg, 2013; 39(7):994–1001.
12.
MiñoDKH, KreutzerTC, Aguirre-RomoI, et al.A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol, 2008; 145(1):136–142.
13.
BushNG, Diez-SantosI, AbbottLR, et al.Quinolones: Mechanism, lethality and their contributions to antibiotic resistance. Molecules, 2020; 25(23).
14.
LevineC, HiasaH, MariansKJ. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta, 1998; 1400(1–3):29–43.
15.
FishDN, ChowAT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet, 1997; 32(2):101–119.
16.
PerryCM, OrmrodD, HurstM, et al.Gatifloxacin: A review of its use in the management of bacterial infections. Drugs, 2002; 62(1):169–207.
17.
SuzukiT, TanakaH, ToriyamaK, et al.Prospective clinical evaluation of 1.5% levofloxacin ophthalmic solution in ophthalmic perioperative disinfection. J Ocul Pharmacol Ther, 2013; 29(10):887–892.
18.
BlondeauJM. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin Investig Drugs, 2000; 9(2):383–413.
19.
BlondeauJM. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol, 2004; 49(Suppl 2):S73–S78.
20.
ZhanelGG, WalktyA, VercaigneL, et al.The new fluoroquinolones: A critical review. Can J Infect Dis, 1999; 10(3):207–238.
EguchiH, NishidaK, HottaF, et al.In vitro antimicrobial activity of quinolones against major bacterial isolates from the ocular surface bacterial flora of tertiary hospital patients in Japan. J Ocul Pharmacol Ther, 2021; 37(2):84–89.
23.
GaoW, XiaT, ChenHB, et al.Ocular bacterial infections at a tertiary eye center in China: A 5-year review of pathogen distribution and antibiotic sensitivity. Int J Ophthalmol, 2020; 13(1):54–60.
24.
ZamoraJL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg, 1986; 151(3):400–406.
25.
McDonnellG, RussellAD. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbiol Rev, 1999; 12(1):147–179.
26.
GrzybowskiA, KanclerzP, MyersWG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol, 2018; 29(1):19–32.
27.
MusumeciR, TroianoP, MartinelliM, et al.Effectiveness of 0.66% povidone-iodine eye drops on ocular surface flora before cataract surgery: A nationwide microbiological study. J Clin Med, 2021; 10(10).
28.
FergusonAW, ScottJA, McGaviganJ, et al.Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: A prospective randomised double blind study. Br J Ophthalmol, 2003; 87(2):163–167.
29.
BarryP, CordovésL, GardnerS. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: Data, dilemmas and conclusions. Eur Soc Cataract Refractive Surgeons, 2013:1–44.
30.
WeissE, ZaharJR, LespritP, et al.Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect, 2015; 21(7):641–649.
31.
TabahA, CottaMO, Garnacho-MonteroJ, et al.A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial De-escalation in the Intensive Care Unit. Clin Infect Dis, 2016; 62(8):1009–1017.
32.
Madaras-KellyK, JonesM, RemingtonR, et al.Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: A modified Delphi approach. Infect Control Hosp Epidemiol, 2014; 35(9):1103–1113.
33.
D’AgataEM, MagalP, OlivierD, et al.Modeling antibiotic resistance in hospitals: The impact of minimizing treatment duration. J Theor Biol, 2007; 249(3):487–499.
CarretG, FlandroisJP, LobryJR. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother, 1991; 27(3):319–327.
36.
TaCN, SinnarS, HeL, et al.Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. Eur J Ophthalmol, 2007; 17(5):689–695.
37.
LiX, LiangX, TangL, et al.Optimal duration for the use of 0.5% LevofloxacinEye drops before vitreoretinal surgery. Asia Pac J Ophthalmol (Phila), 2017; 6(1):40–44.
38.
InoueY, UsuiM, OhashiY, et al.Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: A prospective randomized multicenter study. Jpn J Ophthalmol, 2008; 52(3):151–161.
39.
KimSJ, TomaHS, MidhaNK, et al.Antibiotic resistance of conjunctiva and nasopharynx evaluation study: A prospective study of patients undergoing intravitreal injections. Ophthalmology, 2010; 117(12):2372–2378.
